Tech Titans Investing Millions to Create Genetically Engineered Babies
By Tina Stevens,
CounterPunch
| 12. 11. 2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter Theil and Reddit founder Alexis Ohanian are supplying lavish funds to explore human embryo gene editing and to market “polygenic” (i.e., multi-gene) screening of embryos for quality control.
While their brassy business models boast the goal of eliminating diseases (for which other less risky interventions are available), skeptical experts can sniff an agenda that is peddled more discretely: engineering children to “enhance” traits such as eye color, height, intelligence, and athletic ability. UC Berkeley scientist Fyodor Urnov’s critique is decisive. “These people armed with very poorly deployed sacks of cash are working on “baby improvement,” he said. University of Virginia behavioral geneticist Eric Turkheimer characterized the marketing of unproven probabilistic screening methods as “corporate eugenics.”
Even when disassociated from the eugenic savagery of WWII Nazi Germany, the tech titans’ “techno eugenics” hasten the arrival of bio-entrepreneurially created societies of...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...